• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) a crystalline form of bilastine according to crystalline (polymorph) form 3, wherein the crystalline form has characteristic peaks at 6.47, 12.81, 15.70, and 17.71 ± 0.2 degrees 2-theta in a powder X-ray diffraction pattern, b) a water-soluble filler, and optionally c) a water-insoluble filler. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet comprising dry granulation of a blend of the tablet components and compression of the granules to a tablet, or direct compression of a blend to a tablet. The invention relates further to the medical use of the pharmaceutical composition in the treatment of allergic rhino-conjunctivitis and/or urticaria.
    公开号:ES2773756A2
    申请号:ES201990076
    申请日:2018-12-18
    公开日:2020-07-14
    发明作者:Chaitanya Yogananda Gujjar；Susheel Prakash Uppala；Nani Prasad Donga；Srimannarayana Bandla；Bala Ramesha Chary Rallabandi；Ruslan Staver；Hendrik Schlehahn
    申请人:Alfred E Tiefenbacher GmbH and Co KG；
    IPC主号:
    专利说明:

    [0002] Tablet pharmaceutical composition comprising bilastine form 3 and a water soluble filler
    [0004] The invention relates to a pharmaceutical composition in the form of a tablet, comprising a) a crystalline form of bilastine according to crystalline form 3 (polymorph), wherein the crystalline form has characteristic peaks at 6.47, 12.81, 15 , 70 and 17.71 ± 0.2 degrees 2-theta in a powder X-ray diffraction pattern, b) a water soluble filler, and optionally c) a water insoluble filler. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet comprising dry granulation of a mixture of tablet components and compression of the granules into a tablet, or direct compression of a mixture forming a tablet. The invention further relates to the medical use of the pharmaceutical composition in the treatment of allergic rhinoconjunctivitis and / or urticaria.
    [0006] Background of the invention
    [0008] Bilastine (INN) is known by the chemical name 2- [4- (2- (4- (1- (2-ethoxyethyl) -1 H-benzimidazol-2-yl) piperidin-1-yl) ethyl) phenyl acid ] -2-methylpropionic and CAS number 202189-78-4. It has the following chemical structure:
    [0013] Bilastine is a long-acting, non-sedating histamine antagonist with antagonistic affinity for selective peripheral Hi receptors and no affinity for muscarinic receptors. Its efficacy is similar to cetirizine, fexofenadine, and desloratadine. Bilastine can be classified in the same chemical group as many of the newer antihistamines on the market, although it is not structurally derived, nor is it a metabolite or enantiomer of any of them, but rather an original molecule designed with the intention of satisfying all the requirements of a second generation antihistamine.
    [0014] It was developed by FAES Farma (old name: Fábrica Española de Productos Químicos y Farmacéuticos SA). Bilastine is authorized in the EU for a dose of 20 mg once a day for the relief of symptoms of allergic rhinoconjunctivitis and urticaria in adults and adolescents. FAES and its European licensing partner Menarini market bilastine under different trade names, for example as Bilaska in France and as Bitosen in Germany. Bilastine was first disclosed in patent document EP0818454.
    [0016] Patent document EP1505066 discloses a polymorphic form of bilastine, described as polymorphic form 1. According to patent document EP1505066, bilastine can exist in three different polymorphic forms, called polymorph 1, polymorph 2 and polymorph 3. The procedure described in patent document EP818454 generates a mixture of polymorphs 2 and 3. Polymorph 2, polymorph 3, and their mixture are subsequently converted into polymorph 1 by the procedures of patent document EP1505066, as shown in Examples 1- 5.
    [0018] The BfArM Public Assessment Report (PAR) for FAES bilastine 20 mg tablets reveals similar information, namely that all three polymorphic forms have been identified during the development of bilastine by FAES and that the active substance consists of the form Polymorphic 1. In addition, the PAR discloses that FAES manufactures tablets using direct compression of bilastine with the following excipients: microcrystalline cellulose, sodium carboxymethyl starch (also known as sodium starch glycolate), anhydrous colloidal silica, and magnesium stearate.
    [0020] Patent document WO 2014/026657 (Zentiva) discloses the preparation of polymorphic forms 1 and 2 of bilastine and discloses not only IR data, but also XRD patterns. No particular pharmaceutical compositions or formulations are disclosed.
    [0022] SK 7066 Y1 (Zentiva) discloses the preparation of novel forms of bilastine hydrate called form A dihydrate and form B dihydrate and their XRD data. No particular pharmaceutical compositions or formulations are disclosed.
    [0024] Patent document WO 2017/017301 (Urquima) discloses the preparation of some forms of bilastine hydrate, for example alpha and eta forms, as well as the preparation of polymorphic forms 1, 2, and 3 and their XRD data, IR and DSC. According to patent document WO 2017/017301, the pure polymorphic forms 1 and 2 of bilastine and the alpha and eta hydrates are stable on storage, while the form 3 is converted partially in form 1 leading to a mixture of form 3 with form 1 after 1 month storage at 25 ° C / 60% RH (long-term ICH conditions) and 40 ° C / 75% RH (ICH accelerated conditions), and the phase transformation increases further after 2 months under accelerated conditions to provide a mixture of Form 1 with Form 3. Example 10 of WO 2017/017301 discloses pharmaceutical formulations using the the alpha and eta hydrate forms and with the pure form 2 (polymorphic form 2). The formulations contain the same excipients as the reference product, as described in the PAR, mentioned above. Form 3 formulations are not disclosed. The XRD pattern of the alpha hydrate form in WO 2017/017301 is essentially the same as the XRD pattern of the dihydrate form A, disclosed in patent document SK 7066 Y1 (Zentiva), which leads to the final conclusion that "alpha hydrate" is the same form as "dihydrate form A", just under a different name.
    [0026] Patent document WO2017 / 167949 (KRKA) discloses novel K1 and K2 hydrate forms of bilastine. No particular pharmaceutical compositions or formulations are disclosed. The same K1 and K2 forms are disclosed in IP.com disclosure IPCOM000247653D, along with an additional pure form designated "K3", characterized by XRD, FT-IR and DSC data. The XRD pattern of form K3 in Figure 11 of IPCOM000247653D is essentially the same as the XRD pattern of form 3, disclosed in Figure 7 of patent document WO 2017/017301 (Urquima), leading to the conclusion that the "K3 form" is the same as the "3 form", just a different name. No particular pharmaceutical compositions or formulations are disclosed.
    [0028] Patent document CN106692090A (VENTUREPHARM AVENTIS PHARMA) discloses bilastine tablets and methods for their production based on wet granulation. The use of magnesium aluminum silicate as a lubricant is mentioned. No information is disclosed on the preferred polymorphic forms of bilastine.
    [0030] Although various polymorphous forms of bilastine and pharmaceutical compositions comprising them are provided, further development is required for improved or more efficient means of formulating bilastine using a simplified and reliable method to provide stable formulations for medical administration.
    [0032] Summary of the invention
    [0033] In view of the state of the art, the technical problem underlying the invention was the provision of improved or alternative means for pharmaceutical compositions comprising bilastine that do not have the disadvantages of the state of the art. A further object of the invention was the provision of simplified means for formulating bilastine, preferably simplified means for formulating polymorphic form 3 of bilastine, into a stable composition.
    [0035] This problem is solved by the features of the independent claims. Preferred embodiments of the present invention are provided by the dependent claims.
    [0037] The invention, therefore, relates to a pharmaceutical composition in the form of a tablet, comprising a) a crystalline form 3 of bilastine, wherein the crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0.2 degrees 2-theta in a powder X-ray diffraction pattern, b) a water soluble filler, and optionally c) a water insoluble filler.
    [0039] In one embodiment of the invention, the pharmaceutical composition is characterized in that said composition is prepared by dry granulation of a mixture of components a), b) and optionally c) and compression of the granules into a tablet. In a preferred embodiment, the method is characterized by mixing components a), b) and optionally c), roller compaction and granulation of the mixture, grinding of the granules, lubrication of the granules and subsequent compression of the granules forming a compressed.
    [0041] Dry blending granulation represents an established, cost-effective, reliable and high-throughput approach to formulation, representing an improvement in efficiency and reliability over alternative production methods, for example, compared to granulation in wet followed by subsequent tableting. In one embodiment, the dry granulation of the present invention further represents an inherent description of the structural characteristics of the tablet composition.
    [0043] In one embodiment of the invention, the pharmaceutical composition is characterized in that the composition is prepared by direct compression of a powder mixture of the components of a), b) and optionally c). Direct compression of a powder mixture represents a direct, cost-effective, reliable and high-performance approach to formulation, representing an improvement in efficiency and reliability over alternative production methods, for example compared to wet granulation, followed by tabletting later. In one embodiment, the direct compression of the present invention further represents an inherent description of the structural characteristics of the tablet composition.
    [0045] In one embodiment of the invention, the pharmaceutical composition is characterized in that the composition further comprises a disintegrant, a slipper and / or a lubricant.
    [0047] In one embodiment of the invention, the pharmaceutical composition is characterized in that the water soluble filler is a sugar.
    [0049] In one embodiment of the invention, the pharmaceutical composition is characterized in that the water soluble filler is mannitol.
    [0051] In one embodiment of the invention, the pharmaceutical composition is characterized in that the water soluble filler is lactose.
    [0053] As described in patent document EP0818454, known methods for the manufacture of the bilastine compound can lead to the production of polymorphs 2 and / or 3 of bilastine. Patent document EP1505066 later teaches the production of polymorph 1 from polymorphs 2 and / or 3 having to carry out additional steps. Polymorphic Form 3 also appears to be manufactured using more direct techniques compared to Form 1 or Form 2, thus representing an improved starting point to generate a simplified and alternative option for producing a bilastine composition. However, according to patent document WO 2017/017301, pure polymorphic forms 1 and 2 of bilastine are stable on storage, while form 3 is partially converted to form 1 leading to a mixture of form 3 with Form 1 after 1 month storage under long-term and accelerated ICH conditions.
    [0055] To simplify the production of a pharmaceutical composition comprising bilastine, polymorphic forms 2 and 3 were selected for further formulation studies, due to the absence of the requirement for additional chemical processing that would otherwise be required for the production of polymorph 1.
    [0056] During micronization of pure polymorphic form 2, the presence of form 3 and dihydrate form A is surprisingly observed as polymorphic impurities after jet milling: two out of five batches of the micronized API have shown contamination of the form 2 with form 3 and dihydrate form A. As a further surprise, XRD analysis of API form 3 bilastine before and after micronization shows that the API remains in polymorphic form 3 unchanged during the micronization process.
    [0058] Therefore, to simplify the production of a pharmaceutical composition comprising bilastine, polymorph 3 was selected for further formulation studies, due to the absence of the additional chemical processing requirement that would otherwise be required for the production of polymorph 1, and as it was more stable, compared to form 2, during micronization and allows greater freedom in selecting the required particle size.
    [0060] Thus, an objective of the invention was to identify a simplified stable composition of bilastine and a method of manufacturing a stable composition of bilastine with suitable disintegration and dissolution properties based on the polymorphic form 3.
    [0062] When the polymorphic 3 form of bilastine was formulated using excipients similar to those of the reference product, the dissolution profiles were incomplete compared to the reference product, as can be determined from the dissolution studies below. Although they show acceptable disintegration, dissolution of the formulations using polymorph form 3 and the excipients of the commercial formulation surprisingly showed a significant delay when compared to the commercial formulations using polymorph 1.
    [0064] As a further surprise, the incorporation of a water soluble filler, in particular a sugar, more preferably mannitol or lactose, leads to significantly improved dissolution properties, achieving complete API release, comparable to the commercial reference product.
    [0066] As a further surprise, the inventive tablet compositions prepared using Polymorphic Form 3 are stable and no conversion to Form 1 is observed after storage of accelerated stability, despite the state of the art teaching some polymorphic instability of form 3. The comparative composition containing API of form 2 stored under stress conditions in the ASAP study has shown some contamination with traces of the dihydrate form A, while the inventive composition comprising form 3 of bilastine remains unchanged under the same conditions.
    [0068] Incorporation of a water soluble filler, such as the sugars listed herein, is therefore a preferred embodiment of the formulations described herein employing the polymorphic 3 form. It was completely unexpected that a water soluble filler would allow improved dissolution of the API, when the presence or absence of said water-soluble filler is not a determining factor in disintegration of the tablet.
    [0070] In one embodiment, the invention relates to a pharmaceutical composition as described herein in the form of a tablet, comprising a) a crystalline form 3 of bilastine, b) a water soluble filler, preferably a sugar, such as lactose or mannitol, and c) a glidant.
    [0072] In one embodiment of the invention, the pharmaceutical composition is characterized in that the glidant is silicon dioxide, preferably as colloidal anhydrous silica, magnesium aluminometasilicate and / or talc, preferably a combination of silicon dioxide and magnesium aluminometasilicate.
    [0074] In a preferred embodiment, magnesium aluminometasilicate is employed, and has an unexpected stabilizing effect on the active component bilastine. In particular, polymorphic form 3 is stabilized by magnesium aluminometasilicate in the compositions of the present invention and prevents the formation of bilastine hydrates, as described, for example, in patent documents SK 7066 Y1 and WO 2017 / 017301.
    [0076] The presence of magnesium aluminometasilicate has been shown to impart multiple benefits to the compositions of the present invention, and shows unexpected synergy with bilastine. Magnesium aluminometasilicate also functions as a glidant, providing effective gliding properties that improve the flowability of the mixture of components prior to formulation as a tablet. Furthermore, magnesium aluminometasilicate does not alter the improved dissolution properties of bilastine achieved using a water soluble filler, as discussed in detail below. In addition, magnesium aluminometasilicate exerts a form conversion prevention crystalline 3 in the bilastine hydrate forms, thus enhancing the stability of the API.
    [0077] In addition, the improved dissolution properties of tablets comprising the water-soluble fillers, as disclosed herein, could be maintained for longer periods of time, thus generating a more stable set of dissolution properties, incorporating a glidant. in the tablet, preferably selected from silicon dioxide, preferably as colloidal anhydrous silica, magnesium aluminometasilicate and / or talc. It was completely unexpected that the incorporation of a glidant, most preferably silicon dioxide and magnesium aluminometasilicate, allowed the maintenance of the beneficial dissolution properties allowed by water soluble fillers for long periods of time.
    [0079] Thus, combining a water soluble filler with a glider as described herein, preferably based on the particular examples and specific embodiments disclosed herein, would provide a synergistic effect, i.e., improved dissolution of the API. bilastine when presented as polymorph 3, combined with the prolonged stability of these dissolution properties. One of skill would have derived neither a suggestion nor motivation from the state of the art that excipients as described herein lead to this combination of effects.
    [0081] Furthermore, these two unexpected effects lead to a set of beneficial properties of the pharmaceutical formulation that is greater than the sum of these effects when considered alone. The presence of a glidant, preferably magnesium aluminometasilicate, talc and / or silica would not necessarily provide a beneficial effect alone. The combination of a glidant with a water soluble filler, such as a sugar, provides an unexpected enhancement of the improved dissolution.
    [0083] In one embodiment of the invention, the pharmaceutical composition comprises a crystalline form 3 of bilastine, wherein the crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0.2 degrees 2- theta in a powder X-ray diffraction pattern, a water-soluble filler, a water-insoluble filler, a disintegrant, a glider, and a lubricant, where the water-soluble filler is D-mannitol and the glider is anhydrous silica colloidal or a combination of colloidal anhydrous silica and magnesium aluminometasilicate.
    [0085] In one embodiment of the invention, the pharmaceutical composition is characterized in that the water insoluble filler is microcrystalline cellulose. Microcrystalline cellulose is to be considered a non-limiting preferred embodiment.
    [0087] In one embodiment of the invention, the pharmaceutical composition is characterized in that the disintegrant is selected from sodium starch glycolate, low substituted hydroxypropyl cellulose, pregelatinized starch or crospovidone, preferably sodium starch glycolate or crospovidone.
    [0089] In one embodiment of the invention, the pharmaceutical composition is characterized in that the lubricant is a stearate, preferably magnesium stearate.
    [0091] In one embodiment of the invention, the pharmaceutical composition is characterized in that the water-soluble filler is D-mannitol, the water-insoluble filler is microcrystalline cellulose, the disintegrant is sodium starch glycolate, the glidant is colloidal anhydrous silica or a combination of colloidal anhydrous silica and magnesium aluminometasilicate, and the lubricant is magnesium stearate.
    [0093] In one embodiment of the invention, the pharmaceutical composition is characterized in that the tablet is a coated or uncoated immediate release tablet, preferably uncoated.
    [0095] In one embodiment of the invention, the pharmaceutical composition comprises or consists of:
    [0097] - Bilastine in an amount (% by weight of the tablet) of 10-20%, preferably 12-18%, more preferably 16%;
    [0098] - Mannitol in an amount of 40-70%, preferably 50-65%, more preferably 61%;
    [0099] - Microcrystalline cellulose in an amount of 10-30%, preferably 12-20%, more preferably 14%;
    [0100] - Sodium starch glycolate in an amount of 0.1-5%, preferably 2.5-4.5%, more preferably 4%;
    [0101] - Colloidal anhydrous silica in an amount of 0.1-5%, preferably 2-4%, more preferably 2.8%; and
    [0102] - Magnesium stearate in an amount of 0.1-5%, preferably 1-3%, more preferably 1.6 %.
    [0103] In one embodiment of the invention, the pharmaceutical composition comprises or consists of: - Bilastine in an amount (% by weight of the tablet) of 10-20%, preferably 12-18%, more preferably 16%;
    [0104] - Mannitol in an amount of 40-70%, preferably 50-65%, more preferably 58%;
    [0105] - Microcrystalline cellulose in an amount of 10-30%, preferably 15-25%, more preferably 20%;
    [0106] - Sodium starch glycolate in an amount of 0.1-5%, preferably 0.5-2%, more preferably 1.20%;
    [0107] - Colloidal anhydrous silica in an amount of 0.1-5%, preferably 0.5-2%, more preferably 0.8%;
    [0108] - Magnesium aluminometasilicate in an amount of 0.1-5%, preferably 1 3%, more preferably 2%; and
    [0109] - Magnesium stearate in an amount of 0.1-5%, preferably 1-3%, more preferably 1.6 %.
    [0111] In one embodiment of the invention, the pharmaceutical composition comprises or consists of:
    [0113] - Bilastine in an amount (% by weight of the tablet) of 10-20%, preferably 12-18%, more preferably 16%;
    [0114] - Mannitol in an amount of 40-70%, preferably 50-65%, more preferably 61%;
    [0115] - Microcrystalline cellulose in an amount of 10-30%, preferably 12-20%, more preferably 14%;
    [0116] - Sodium starch glycolate in an amount of 0.1-5%, preferably 2.5-4.5%, more preferably 4%;
    [0117] - Colloidal anhydrous silica in an amount of 0.1-5%, preferably 0.5-2%, more preferably 0.8%;
    [0118] - Magnesium aluminometasilicate in an amount of 0.1-5%, preferably 1 3%, more preferably 2%; and
    [0119] - Magnesium stearate in an amount of 0.1-5%, preferably 1-3%, more preferably 1.6%.
    [0121] In a preferred embodiment, the composition preferably refers to BIL / FON2, BIL / F3, BIL / F4, and BIL / F6, or alternative formulations based closely on these embodiments, as demonstrated below, in particular compositions with amounts of components that fall within the ranges indicated by the "% range" parameters disclosed below.
    [0123] The following embodiments can also be considered to encompass additional embodiments of the invention in which the indicated amounts of the components are employed, but alternative water-soluble fillers, water-insoluble fillers, disintegrators, glidants and / or lubricants, other than the specific components disclosed below.
    [0125] BIL / FON2 based realizations:
    [0127]
    [0129] Realizations based on BIL / F3 and BIL / F4:
    [0130]
    [0132]
    [0134] BIL / F6 based realizations:
    [0135]
    [0137]
    [0140] In the possible embodiments based on BIL / FON2, BIL / F3, BIL / F4 and BIL / F6, the total amount of glidant and / or lubricant, added either in stage A and / or in stage B, is preferably of 0.1-5% based on the total weight of all tablet components.
    [0142] The invention further relates to a pharmaceutical composition as described herein for use as a medicament in the treatment of allergic rhinoconjunctivitis and / or urticaria. Thus, the invention relates to the use of a pharmaceutical composition as described herein in the manufacture of a medicine for the treatment of allergic rhinoconjunctivitis and / or urticaria. The invention further relates to a method of treating allergic rhinoconjunctivitis and / or urticaria, which comprises administering to a patient in need thereof a pharmaceutical composition according to the composition described herein, preferably a composition comprising a therapeutically relevant or effective amount of bilastine.
    [0144] The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet, which comprises dry granulation of a mixture and compression of the granules into a tablet, wherein the mixture comprises a) a crystalline form 3 of bilastine, where crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0.2 degrees 2-theta in a powder X-ray diffraction pattern, b) a water soluble filler and optionally c) a water insoluble filler.
    [0146] In a preferred embodiment, the method comprises mixing components a), b) and optionally c), roller compaction and granulation of the mixture, grinding the granules, lubrication of the granules and subsequent compression of the granules into a tablet.
    [0148] A dry granulation method is surprisingly advantageous with respect to minimizing the impact of API variability on processing.
    [0150] The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet, which comprises direct compression of a powder mixture, wherein said powder mixture comprises a) a crystalline form 3 of bilastine, wherein the crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0.2 degrees 2-theta in an X-ray powder diffraction pattern, b) a water soluble filler and optionally c) a filler insoluble in water.
    [0152] As shown below in more detail, by way of examples, the method of the present invention enables a direct, cost-effective, reliable, and high-throughput approach to bilastine formulation, representing an improvement in efficiency and reliability over production alternatives. The method is capable of producing stable formulations of bilastine, with excellent content uniformity within the specification limits according to the European Pharmacopoeia 2.9.40 independent of changes in mixing parameters (pre-lubrication time, lubrication time and mixer speed ).
    [0153] In some embodiments, wet granulation or other methods involving wet processing components are not employed. Dry production methods are preferred, such as dry granulation or direct compression. As shown below, the experiments have been carried out using the wet granulation methods and the compositions described in patent document CN106692090A. These experiments reveal that wet granulation of either Polymorphic Form 2 or 3 in the compositions described therein leads to conversion to the "Alpha Form" as described in patent document WO 2017/017301, otherwise known as "Dihydrate Form A". Furthermore, wet granulation appears to have a detrimental effect on the dissolution properties of the API.
    [0155] In one embodiment of the invention, the method of preparing the pharmaceutical composition is characterized in that the method comprises:
    [0157] - Dispense the mixture components, which preferably comprise a) a crystalline form 3 of bilastine, wherein the crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0.2 degrees 2 -theta in a powder X-ray diffraction pattern, b) a water soluble filler and optionally c) a water insoluble filler;
    [0158] - Sift the bilastine and the load (s) as a mixture through a suitable mesh; - Optionally, sieve the disintegrant, slider (s) and lubricant separately through a suitable mesh (this stage can also be combined with the previous stage, which allows a single sieving stage);
    [0159] - Load the above materials (preferably with the exception of the lubricant or with only a portion of the lubricant) in a mixer and mix for a sufficient time to mix the components (pre-lubrication mix);
    [0160] - Dry granulation of the mixture, preferably using roller compaction; - Optionally, grinding the granules to achieve the desired granule size; - Optionally, add the lubricant (if not already incorporated or add the remaining portion of the lubricant) or a combination of lubricant with slider (s) and continue mixing long enough to mix the granules with the lubricant or lubricant combination with slider (s) (lubrication mixture);
    [0161] - Compress the granules into tablets using the granules (lubricated) from the previous stage.
    [0162] In one embodiment of the invention, the method of preparing the pharmaceutical composition is characterized in that the method comprises:
    [0163] - Dispense the mixture components, preferably comprising a) a crystalline form 3 of bilastine, wherein the crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0.2 degrees 2 -theta in a powder X-ray diffraction pattern, b) a water soluble filler and optionally c) a water insoluble filler;
    [0164] - Sift the bilastine and the load (s) as a mixture through a suitable mesh; - Optionally, sieve the disintegrant, slider (s) and lubricant separately through a suitable mesh;
    [0165] - Load the above materials, preferably with the exception of the lubricant, in a mixer and mix for a sufficient time to mix the components (pre-lubrication mix);
    [0166] - Optionally, add the lubricant (if it has not already been incorporated) and continue mixing long enough to mix the components (lubrication mixture);
    [0167] - Compress the tablets using the mixture from the previous stage.
    [0169] In one embodiment of the invention, the method of preparing the pharmaceutical composition is characterized in that the pre-lubrication mixing is carried out for 1-60 minutes, preferably 5-30 minutes, more preferably 8-25 minutes, in particular 10 , 15 or 20 minutes.
    [0171] In one embodiment of the invention, the method of preparing the pharmaceutical composition is characterized in that the lubrication mixture is carried out for 0-30 minutes, preferably 1-10 minutes, more preferably 2-8 minutes, in particular 3, 5 or 7 minutes.
    [0173] In one embodiment of the invention, the method of preparing the pharmaceutical composition is characterized in that the mixing is carried out in a mixer with 5-100 rpm, preferably 5-40 rpm, in particular 10, 20 or 30 rpm of mixing speed. .
    [0175] Detailed description of the invention
    [0177] "Bilastine" or (2- [4- (2- (4- (1- (2-ethoxyethyl) -1H-benzimidazol-2-yl) piperidin-1-yl) ethyl) phenyl] -2-methylpropionic acid name) , registered under CAS number 202189-78-4, is known as a second-generation antihistamine drug for the treatment of rhinoconjunctivitis allergic and urticaria (hives). It exerts its effect as a selective histamine H1 receptor antagonist, and has similar efficacy to cetirizine, fexofenadine and desloratadine. Bilastine is licensed in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria.
    [0179] The term "bilastine" as used herein in accordance with the present invention includes bilastine in free base form, a pharmaceutically acceptable salt thereof, amorphous bilastine, crystalline bilastine, preferably selected from the polymorphic forms described herein document, any isomer, derivative, hydrate, solvate or prodrug, or a combination thereof.
    [0181] Bilastine or its polymorphs can also be prepared as a pharmaceutical salt. Examples of pharmaceutical acceptable salts of bilastine that can be contained as an active ingredient in a solid oral dosage form include the acid addition salt formed with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like; acid addition salts formed with organic acids such as acetic acid, propionic acid, butyric acid, oxalic acid, citric acid, succinic acid, tartaric acid, fumaric acid, malic acid, lactic acid, adipic acid, benzoic acid, salicylic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, glutamic acid, aspartic acid, and the like. Examples of the solvate include solvates with water, ethyl alcohol, or the like.
    [0183] Polymorphic forms 1,2 and 3 of bilastine are known from the state of the art, for example, in the descriptions of patent documents EP1505066, WO 2014/026657 and WO 2017/017301.
    [0185] All references to "polymorph form I", "polymorph form 1", "polymorph 1", "polymorph I", "form 1" or "form I", "crystalline form 1" or " crystalline form I "or the like.
    [0187] Form 1, described in Example 12 of patent document WO 2014026657, refers to a crystalline form with the following characteristics:
    [0189] XRPD ([° 2Th.] (% Int.)): 3.64 (4.4), 10.57 (23.3), 11.27 (78.1), 12.47 (38.8 ), 14.08 (26.9), 15.07 (38.4), 15.50 (16.5), 16.27 (43.6), 17.16 (100.0), 18.89 (71.8), 19.73 (74.0), 21.13 (33.9), 22.17 (18.1), 22.71 (26.9), 23.34 (10.3) , 24.88 (18.6), 25.82 (9.2), 26.58 (11.5), 28.43 (9.7), 29.16 (8.8), 30.92 (4.6), 34.38 (9.5), 37.01 (5.4).
    [0191] Figure 1 of patent document WO2017 / 017301 shows the XRD pattern of form 1 with the same peak positions as the pattern of form 1 disclosed in Figure 7 of patent document WO 2014/026657.
    [0193] The inventors have also analyzed form 1 bilastine and found that the characteristic diffraction peaks are present at 10.57, 11.27, 12.44, 14.08, 15.07, 15.50, 16.27 and 17 , 16 ± 0.2 ° 2Theta.
    [0195] For monitoring the presence of bilastine form 1 in tablets, the most suitable peaks are the characteristic, non-interfering reflections at 12.47 and / or 14.08 ± 0.2 ° 2 Theta.
    [0197] Bilastine dihydrate form A is known from the state of the art, for example in the description of patent document SK 7066 Y1. According to patent document SK 7066 Y1, the dihydrate form A has characteristic peaks at 8.1, 11.5, 13.8, 17.6, 20.0, 21.1 and 23.2 ± 0.2 degrees 2-theta in a powder X-ray diffraction pattern. According to Table 1 of patent document SK 7066 Y1, the following relative intensity is measured at these positions: XRPD ([° 2Th.] (% Of int. Laugh)): 8.26 (10.5), 8, 06 (100.0), 10.86 (20.8), 11.50 (45.7), 12.15 (20.2), 13.84 (50.5), 17.59 (77.4 ), 18.52 (47.0), 18.76 (41.0), 20.04 (33.9), 21.08 (32.1), 23.22 (19.6), 26.17 (17.5).
    [0199] However, from the analysis of the dihydrate form A by the present inventors, it seems that an error is evident in the list provided in patent document SK 7066 Y1. There is no peak in the XRD pattern visible at 8.1. Based on the separation d of 10.155, the calculated position should be 8.70 ° 2Th. This value is in line with the present inventors' measurements, where no peak is present at 8.1, but a strong peak is visible at approximately 8.7 ° 2Th.
    [0201] Patent document WO 2017/017301 (Urquima) discloses the preparation of the alpha hydrate form of bilastine and its XRD, IR, and DSC data. The XRD pattern of the alpha hydrate form in WO 2017/017301 is essentially the same as the XRD pattern of the dihydrate form A, disclosed in SK 7066 Y1 (Zentiva), which leads concluding that "alpha hydrate" is the same form as "dihydrate form A", just under a different name.
    [0202] According to the present invention, dihydrate form A has characteristic peaks at 8.7, 11.5, 13.8, 17.6, 20.0, 21.1 and 23.2 ± 0.2 degrees 2-theta in a powder X-ray diffraction pattern. Furthermore, the dihydrate form A has additional characteristic peaks at 8.3, 10.9, 12.2, 18.5, 18.8, and 26.2 ± 0.2 degrees 2-theta in a ray diffraction pattern. X of dust. The following relative intensity is measured at these positions:
    [0204] XRPD ([° 2Th.] (% Of int. Laughing)): 8.26 (10.5), 8.70 (100.0), 10.86 (20.8), 11.50 (45, 7), 12.15 (20.2), 13.84 (50.5), 17.59 (77.4), 18.52 (47.0), 18.76 (41.0), 20, 04 (33.9), 21.08 (32.1), 23.22 (19.6), 26.17 (17.5).
    [0206] The inventors have prepared bilastine dihydrate form A by suspending form 2 bilastine in water for 1 day at room temperature or 40 ° C. Alternatively, the dihydrate form A is prepared by suspending form 3 bilastine in water for 1 day at 40 ° C.
    [0208] The inventors analyzed the A dihydrate form of bilastine and found that most of the characteristic peaks were present at 8.7, 12.2, 13.8 and 17.6 ± 0.2 degrees 2-theta in a diffraction pattern. X-ray powder.
    [0210] In tablets containing the crystalline form 2 of bilastine and traces of the dihydrate form A of bilastine, only the non-interfering peak of the dihydrate form A at 8.7 ± 0.2 degrees 2-theta is detectable in the pattern of X-ray powder diffraction between reflections of crystalline form 2 of bilastine and excipients.
    [0212] In tablets containing the crystalline form 2 of bilastine and a minor amount of the dihydrate form A of bilastine, only the non-interfering peaks of the dihydrate form A at 8.7 and 12.2 ± 0.2 degrees 2-theta they are detectable in the X-ray powder diffraction pattern between reflections of the crystalline form 2 of bilastine and excipients.
    [0214] All references to "polymorph form II", "polymorph form 2", "polymorph 2", "polymorph II", "form 2" or "form II", "crystalline form 2" or " crystalline form II "or the like.
    [0216] Form 2, described in Example 12 of patent document WO 2014026657, refers to a crystalline form with the following characteristics:
    [0217] XRPD ([° 2Th.] (% Int. Laughing)): 6.53 (100.0), 9.43 (30.8), 11.04 (22.8), 13.39 (6, 2), 15.24 (32.2), 15.86 (86.1), 18.07 (29.9), 18.39 (36.2), 18.94 (8.3), 20, 19 (16.0), 20.66 (19.0), 21.70 (17.1), 22.17 (15.6), 23.70 (5.7), 26.59 (4.9 ), 28.03 (3.6), 28.33 (3.6), 29.70 (4.3).
    [0219] Figure 4 of patent document WO2017 / 017301 shows the XRD pattern of form 2 with essentially the same peak positions as the pattern of form 2 disclosed in Figure 9 of patent document WO 2014/026657.
    [0221] The inventors have also analyzed form 2 bilastine and found that the characteristic diffraction peaks are present at 6.53 °, 15.24 °, 15.86 ° and 18.07 ° ± 0.2 degrees 2-theta.
    [0223] In some embodiments, two additional reflections (characteristic diffraction peaks) at 9.43 ° and 11.04 ° ± 0.2 degrees 2-theta can be employed, which are also characteristic and highly visible in XRPD analyzes performed despite of placebo signals, for a definition of the crystalline form 2.
    [0225] Preferably, the characteristic reflections for form 2 are 6.53 °, 9.43 °, 11.04, 15.24 °, 15.86 ° and 18.07 ° ± 0.2 ° 2Theta.
    [0227] The powder X-ray diffraction pattern of tablets containing only bilastine form 2 as API shows characteristic peaks at 6.53 °, 15.24 °, 15.86 ° and 18.07 ° ± 0.2 ° 2Theta , while no characteristic peaks are observed for form 1, for example at 12.47 and / or 14.08 ± 0.2 ° 2Theta, and for the dihydrate form A, for example at 8.7 ± 0.2 2Theta (and optionally at 12.2 ± 0.2 ° 2Theta).
    [0229] In embodiments of the present invention, polymorph 3 form is preferred. All references to "polymorph form III", "polymorph form 3", "polymorph 3", "polymorph III", "form 3 "or" form III "," crystalline form 3 "or" crystalline form III "or the like.
    [0231] Figure 7 of patent document WO 2017/017301 reveals the XRD pattern of polymorphic form 3 of bilastine. According to patent document WO 2017/017301, the pure polymorphic forms 1 and 2 of bilastine and the alpha and eta hydrates are stable with storage, while form 3 is partially converted into form 1 which leads to a mixture of form 3 with form 1 after 1 month storage at 25 ° C / 60% RH (long-term ICH conditions) and 40 ° C / 75% RH (accelerated ICH conditions) , and the phase transformation increases further after 2 months under accelerated conditions to provide a mixture of Form 1 with Form 3.
    [0233] IPCOM000247653D disclosed XRD data for the so-called "K3 form" of bilastine. The XRD pattern of Form K3 in Figure 11 of IPCOM000247653D is essentially the same as the XRD pattern of Form 3, disclosed in Figure 7 of patent document WO 2017/017301, leading to the conclusion that the "Form K3" is the same as "form 3", just a different name. According to IPCOM000247653D, this form of bilastine is characterized by a short list of 3 characteristic peaks at 15.7, 17.7, and 20.2 ± 0.2 ° 2-theta or by a preferred longer list of 10 peaks at 6 , 5, 9.3, 10.9, 12.8, 15.7, 17.7, 18.4, 20.2, 22.0, and 27.4 ± 0.2 ° 2Theta.
    [0235] The inventors have also analyzed form 3 bilastine and found that the characteristic diffraction peaks are present at 6.47, 9.29, 10.92, 12.81, 15.70, 17.71, 18.38, 20 , 17, 21.97 and 27.36 ± 0.2 ° 2Theta in an X-ray powder diffraction pattern.
    [0237] Preferably, the characteristic reflections for form 3 are 6.47, 12.81, 15.70 and 17.71 ± 0.2 ° 2Theta.
    [0239] The powder X-ray diffraction pattern of tablets containing only bilastine form 3 as API shows characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0.2 ° 2Theta, whereas no characteristic peaks are observed for form 1, for example at 12.47 and / or 14.08 ± 0.2 ° 2Theta, and for dihydrate form A, for example at 8.7 ± 0.2 ° 2Theta (and optionally at 12.2 ± 0.2 ° 2Theta).
    [0241] The term "essentially the same" with reference to PXRD means that variabilities in peak positions and relative peak intensities are to be taken into account. For example, a typical precision of 2-Theta values is in the range of ± 0.2 ° 2-Theta. Thus, for example a diffraction peak that normally appears at 15.7 ° 2-Theta, for example, can appear between 15.5 ° and 15.902-Theta in most X-ray diffractometers under standard conditions. With respect to the relative intensities and characteristic peaks of the aforementioned X-ray powder diffraction patterns, the given relative intensity values are not intended to limit the identification of the mentioned characteristic peaks. As it is known To an expert, the relative peak intensities will show inter-apparatus variability, batch-to-batch variability, as well as variability due to degree of crystallinity, preferred orientation, sample preparation, and as such are provided as an indication and as qualitative measures only, but not a limiting definition, of the intensities of the peaks in the X-ray powder diffraction patterns. The term "characterizing peak" in the context of the definition of the present invention is therefore not limited to the respective relative intensities given above, and any one or more of the respective peaks can be determined as the characterizing peak for any given shape. of bilastine. Preferably, at least 1,2, 3 or 4 peaks are used to characterize a polymorphic form of bilastine, in other embodiments, at least 5, 6, 7, 8, 9 or 10 peaks can be used.
    [0243] The term "active ingredient" or "API" herein refers to a pharmaceutically active molecule (eg, bilastine), as well as its salts, esters, amides, prodrugs, metabolites, enantiomers, polymorphs, analogs, etc., pharmaceutically acceptable and therapeutically active, which induce a desired pharmacological or physiological effect. Terms such as "active", "active agent", "active substance" can be used synonymously with "active principle".
    [0245] The terms "effective amount" or "therapeutically effective amount", used interchangeably, are defined to mean the amount of active drug (eg, bilastine) that is sufficient to elicit an appreciable biological response when administered to the patient. It will be appreciated that the precise therapeutic dose will depend on the age and condition of the patient and the nature of the condition to be treated and will be at the final discretion of the attending physician.
    [0247] The term "excipient" means a pharmacologically inactive component such as a diluent, a disintegrant, a carrier, and the like of a pharmaceutical product. Excipients that are useful in the preparation of a pharmaceutical composition are generally safe, non-toxic, and are acceptable for veterinary as well as human pharmaceutical use. Reference to an excipient includes both one excipient and more than one excipient.
    [0249] Excipients are described herein in some embodiments according to "% by weight" or "% by weight". The% by weight values quoted herein preferably refer to the percentage of material by weight present in the tablet or powder mixture before compression.
    [0250] According to the invention, a water-soluble filler can be used, ie as a bulking agent. Various useful water soluble fillers include, but are not limited to, sugars, such as mannitol, lactose, sorbitol, xylitol, and the like, and mixtures thereof; they are more preferably selected from mannitol and lactose.
    [0252] According to the invention, a water insoluble filler can be used. Various useful water insoluble fillers include, but are not limited to, starch, powdered cellulose, microcrystalline cellulose (MCC), calcium phosphate, and the like, or combinations thereof.
    [0254] According to the present invention, one or more lubricants can be used. Useful lubricants include, but are not limited to, stearates, such as magnesium stearate or sodium stearyl fumarate.
    [0256] According to the present invention, one or more glides can be used. Useful glidants include, but are not limited to, silica, in various forms, such as colloidal silicon dioxide, magnesium aluminometasilicate (also known as Neusilin®), magnesium silicate, magnesium trisilicate, talc, and other forms of magnesium dioxide. silicon, such as added silicates and hydrated silica.
    [0258] Magnesium Aluminometasilicate (also known as Silodrate or Simaldrate) typically comes as a white powder, grain, or granule. It is commonly known according to the following formula Al202.2Mg.3C> 3Si with a MW of 362.821 g / mol. Magnesium aluminometasilicate can also be identified with the following formula Al2H2Mg20i2S¡3 with a MW of 380.832 g / mol. Magnesium aluminometasilicate can also be identified with the following formula Al203.Mg0.1.7Si02.xH20 (CAS number 12511 31-8). In a preferred embodiment, the magnesium aluminometasilicate is used as Neusilin®, which is a fine granule of magnesium aluminometasilicate.
    [0260] According to the present invention, a disintegrant is normally an agent used in the preparation of solid pharmaceutical formulations that causes them to disintegrate and release their medicinal substances in contact with moisture. Disintegrators include, but are not limited to, hydroxypropyl cellulose (L-HPC), pregelatinized starch (PGS), crospovidone, croscarmellose sodium, sodium starch glycolate, and the like.
    [0262] The composition may also comprise other excipients, such as surfactants and / or binders, as desired.
    [0264] A "tablet", as used herein, is considered a solid unit dosage form of a medicament comprising one or more excipients.
    [0266] The most commonly used solid dosage forms today include granules, pellets, tablets, and capsules. Tablets are solid dosage forms containing active ingredients with one or more excipients prepared by any compression or molding method. The basic technique of tableting by three well known methods includes direct compression, wet granulation, and dry granulation. According to the present invention, dry granulation and direct compression are preferred. Dry granulation can normally be employed if the materials have sufficient inherent bonding or cohesive properties to form granules. Dry granulation normally refers to the granulation process without the use of liquids. Two methods of dry granulation are mainly used in the pharmaceutical industry, namely pre-compression and roller compaction. In a roller compactor the material particles are consolidated and densified by passing the material between two rollers under high pressure. The densified material from a roller compactor is then reduced to uniform granule size by grinding. Roller compaction / dry granulation (RCDG) is a method of choice for the processing of drugs that are physically or chemically sensitive to moisture, as no liquid binder is required in granulation, and is a preferred method of the present invention.
    [0268] In the dry granulation method of tablet production, the dry ingredients are thoroughly mixed to give a mixture, the mixture is granulated, for example by roller compaction and granulation and optionally milling, and then the granules are compressed into tablets. This eliminates the drying steps associated with the wet granulation method. It also reduces the higher costs involved in wet granulation which include high equipment, labor, time, process validation and energy expenditure. As a result, dry granulation is both efficient and economical, well suited for the production of high-quality tablets, exhibiting hardness, low friability, and excellent dissolution rates. As an added benefit, dry granulation can prevent unwanted polymorphic conversion of the anhydrous solid form of API to a hydrate form during tabletting, and can also improve the physical and chemical stability of tablets in compared to wet granulation.
    [0270] In the direct compression method of tablet production, the dry ingredients are thoroughly mixed into a powder blend and then compressed into tablets. This eliminates the drying steps associated with the wet granulation method. It also reduces the higher costs involved in wet granulation which include increased equipment, labor, time, process validation and energy expenditure. As a result, direct compression is both beneficial and economical, well suited for the production of high-quality tablets, exhibiting hardness, low friability, and excellent dissolution rates. As an added benefit, direct compression can prevent unwanted polymorphic conversion of the anhydrous solid form of API to a hydrate form during tablet manufacture, and can also improve the physical and chemical stability of tablets compared to granulation in damp.
    [0272] According to the invention, a powder or powder mixture is compressed, which is a substantially dry solid, preferably composed of a large number of fine particles that can flow when shaken or tilted. The powder of the present invention is preferably distinguishable from granules, which are normally prepared by wet or dry granulation, and are usually larger than the particles of the powder of the invention. According to one embodiment of the invention, the powder mixture is directly compressed.
    [0274] The methods of compressing tablets are known to a skilled person and can be appropriately chosen without undue effort. For example, after mixing the ingredients (in the case of direct compression), the powder mixture can be directly compressed to obtain a tablet. Methods of compressing granules into tablets are also known to one of skill, wherein the granules are subsequently compressed into tablets. Compression is preferably carried out by a single punch machine (stamping press) or by a multi-station machine (rotary press). The tablet press is a high speed mechanical device. It 'squeezes' ingredients into the required tablet shape with extreme precision. They can prepare the tablet in many shapes, although they are usually round or oval. Therefore, you can press the name of the manufacturer or the product on top of the tablet. Allergic rhinoconjunctivitis or rhinitis, or allergic rhinitis or hay fever, is usually caused by an inflammation in the nose that occurs when the immune system overreacts to allergens in the air. Rhinitis is characterized by nasal congestion, runny nose, post-nasal drip, sneezing, red eyes, and / or itchy nose or eyes. Allergic rhinitis is normally associated with the presence of antibodies (IgE) that recognize certain allergens. When these antibodies are exposed to the allergen, they bind to the allergen and this leads to an inflammatory reaction. This reaction is characterized by the release of various inflammatory mediators, which in turn leads to the typical signs and symptoms of allergic rhinitis.
    [0276] Urticaria, or hives, is a vascular reaction of the skin marked by the transitory appearance of smooth plaques (hives). Individual lesions usually resolve without scarring within several hours. Most cases of urticaria are self-limited and short-lived; the rash rarely lasts more than several days, but can recur for weeks. Chronic urticaria is also treatable using the API as described herein. A medical professional is able to choose a suitable dose of the tablet described herein for the treatment of allergic rhinoconjunctivitis or urticaria, depending on the age and size of the patient, and the severity of the disease or other relevant factors.
    [0278] Figures
    [0280] The invention is demonstrated by way of the figures disclosed herein. The figures provide support for a detailed description of potentially preferred non-limiting embodiments of the invention.
    [0282] Fig. 1 shows the XRD of API bilastine form 1 powder.
    [0284] Fig. 2 shows the XRD of API bilastine form 2 powder (non-micronized API, "as is" from synthesis)
    [0286] Fig. 3 shows the XRD of API bilastine form 3 powder (non-micronized API, "as is" from synthesis)
    [0288] Fig. 4 shows the XRD of API bilastine powder in jet mill micronized form to Dgo (Malvern, by volume) of 8.14 microns.
    [0290] Fig. 5 shows the powder XRD of API bilastine dihydrate form A.
    [0291] Fig. 6 shows the XRD of BIL / CX (Initial) tablet powder.
    [0293] Fig. 7 shows the XRD of BIL / CX tablet powder (40 ° C / 75% RH, 1 month in Alu-Alu blister).
    [0295] Fig. 8 shows the XRD of BIL / CX tablet powder (50 ° C / 75% RH, 14 day open exposure).
    [0297] Fig. 9 shows the XRD of BIL / F3 tablet powder (40 ° C / 75% RH, 1 month in Alu-Alu blister).
    [0299] Fig. 10 shows the XRD of BIL / F6 (Initial) tablet powder.
    [0301] Fig. 11 shows the XRD of BIL / F6 tablet powder (40 ° C / 75% RH, 2 months in Alu-Alu blister).
    [0303] Fig. 12 shows the XRD of BIL / F6 tablet powder (50 ° C / 75% RH, 14 day open exposure).
    [0305] Examples
    [0307] The invention is demonstrated by way of the examples disclosed herein. The examples provide technical support for a detailed description of potentially preferred non-limiting embodiments of the invention.
    [0309] General procedure for the preparation of the following examples using a direct compression process:
    [0311] 1.0 Dispense the materials according to the quantities indicated.
    [0312] 2.0 Sieve bilastine and load (s) through a suitable mesh
    [0313] 3.0 Sieve disintegrant, slider (s) and lubricant separately through suitable mesh.
    [0314] 4.0 Load the materials from stages 2.0 and 3.0, except the lubricant, into the mixer and mix for sufficient time.
    [0315] 5.0 Add lubricant from stage 2.0 to 4.0 and continue mixing long enough.
    [0316] 6.0 Compress the tablets using the mixture from step 5.0.
    [0318] General procedure for the preparation of the examples below using a dry granulation process:
    [0320] 1.0 Dispense the materials according to the quantities indicated.
    [0321] 2.0 Sift bilastine and load (s) through the appropriate mesh.
    [0322] 3.0 Sift disintegrant, slider (s) and lubricant separately through the appropriate screen.
    [0323] 4.0 Load Stage A materials from Stages 2.0 and 3.0 above into the mixer and mix long enough.
    [0324] 5.0 The mixture from step 4.0 is compacted by roller to prepare the granules.
    [0325] 6.0 The compacts are crushed using Quadro® Cornil® to get granules of suitable size.
    [0326] 7.0 Load the granules from step 6.0 into the mixer. Add the excipients from Step B (eg second portion of sieved magnesium stearate and optionally colloidal anhydrous silica) to the mixer and continue mixing for sufficient time.
    [0327] 8.0 Compress the tablets using the lubricated mixture from Step 7.0.
    [0329] Part A - Comparative Examples
    [0331] Comparative example BIL / CE1 (direct compression process):
    [0333]
    [0334]
    [0337] Comparative example BIL / CE2 (dry granulation process):
    [0339]
    [0342] Comparative example BIL / CE3 (direct compression process):
    [0344] This example corresponds essentially to Example 10D of patent document WO 2017/017301, which uses polymorphic form 2 of bilastine, while form 3 is used below:
    [0348] BIL / CE4 comparative example (direct compression process, using form 2 API ):
    [0349] This comparative example is the revision of Example 10D of patent document WO 2017/017301, which employs polymorphic form 2 of bilastine.
    [0352] Additional example:
    [0353] BIL / CX example (direct compression process, using API form 2)
    [0354]
    [0355]
    [0357] Inventive examples
    [0358] BIL / FON1 example (direct compression process):
    [0362] Example BIL / FON2 (dry granulation process):
    [0365]
    [0367] Example BIL / F3) (dry granulation process):
    [0371] Example BIL / F4 (dry granulation process):
    [0372] The composition BIL / F4 is obtained exactly as Example BIL / F3, but using API micronized by jet mill. The non-micronized API ("as is" from the synthesis) was used in the above example BIL / F3.
    [0373] The API Dgo (volume, Malvern) particle size distribution is 8.14 microns in Example BIL / F4 and 35.8 microns in BIL / F3.
    [0374] Example BIL / F5 (dry granulation process):
    [0377] Example BIL / F6 (dry granulation process):
    [0378]
    [0379]
    [0382] Physical parameters of the tablets:
    [0384]
    [0387] Part c
    [0389] Disaggregation study:
    [0391] The disintegration time of the tablets was determined according to the American Pharmacopoeia (USP) test for uncoated tablets in deionized water at 37 ° C. The reported result is an average of 6 measurements. How can Determine from the data below, the disintegration time is very short for Bitosen® and comparative examples (less than 20 s) and short for all other examples (less than 2.5 minutes).
    [0396] Part d
    [0398] Dissolution study:
    [0400] For the tablet formulations of inventive examples and comparative examples, dissolution testing was carried out according to the following dissolution test methods and conditions.
    [0402] Conditions and methods of dissolution:
    [0404] The QC release medium was tested using tablets at a paddle speed of 50 revolutions per minute (RPM) according to method 2 (paddle) of the USP dissolution test, using 900 ml of acetate buffer at pH 4 ,5. The temperature of the medium is kept at 37 ° C ± 0.5 ° C using a water bath. Sample solutions were obtained at 5, 10, 15, 20, 30, 45 and 60 minutes after starting the test and filtered through a 0.45 µm PVDF Millipore syringe filter.
    [0406] Similarly, the solution is tested under the biorelevant conditions: 250 ml of acetate buffer at pH 4.5, method 2 (paddle) with PEAK containers at a paddle speed of 30 RPM.
    [0409] The 2nd biorelevant conditions (mainly used for the evaluation of compositions with form 2) are the same as before, but with the paddle speed of 25 RPM instead of 30 RPM.
    [0411] Details of the analytical dissolution test method:
    [0413] Equipment:
    [0415] - A high performance liquid chromatography system with isocratic elution capability, a spectrophotometric UV detector, and an autosampler (Waters Alliance 2695 separations module, Waters 2487 dual A absorbance detector, or equivalent).
    [0416] - Data manipulation system (Waters Empower workstation or equivalent).
    [0417] - Analytical column: A 150 mm lake stainless steel column, 4.6 mm internal diameter filled with particles of octadecylsilylsilica as stationary phase with size 3.5 | a, m. (Use: Xterra RP18, 150mm length, 4.6mm ID, 3.5 | a, m particle size or equivalent).
    [0418] - Dissolution meter (brand: Electrolab, model TDT-08L or equivalent).
    [0420] Preparation of analytical solutions:
    [0422] Buffer: Prepare anhydrous 10 mm dipotassium hydrogen phosphate. For example, transfer 1.76 gm of anhydrous dipotassium hydrogen phosphate to a beaker containing 1000 ml of Milli-Q grade water. Adjust the pH to 6.8 with dilute orthophosphoric acid. Filter through a 0.45 | a, micron or finer porosity membrane filter and degas.
    [0424] Mobile phase: Buffer: Acetonitrile (65:35 v / v).
    [0426] Preparation of diluent: Mix water and acetonitrile in the ratio of 50:50 (v / v) and degas.
    [0428] Preparation of dissolution media: Prepare acetate buffer solution at pH 4.5 in purified water as mentioned in Ph. Eur. 5.17.1 For example: Dissolve 29.9 g of sodium acetate trihydrate and 16.6 ml of acetic acid in a beaker of 10,000 ml containing 8,000 ml of purified water. Dissolve and dilute to 10,000 ml with water and mix. Adjust the pH to 4.5 if necessary, with acetic acid or dilute sodium hydroxide solution.
    [0430] Standard solution: Prepare a solution containing 0.022 mg / ml of bilastine in diluent. For example, weigh and transfer approximately 22 mg of bilastine working standard into a clean, dry 50 ml volumetric flask, add approximately 10 ml of diluent, and sonicate until dissolved. Add an additional 30 ml of solution medium and sonicate for 2 minutes. Make up the volume with dissolution medium. Dilute 5 ml to 100 ml with dissolving medium. Prepare it in duplicate.
    [0432] Sample dissolution: Set the instrument parameters as mentioned above. Place one tablet in each of six containers containing the dissolution medium, which has been equilibrated to 37 ° C ± 0.5 ° C, and start the dissolution meter. At the specified time interval, withdraw the sample solution from each container. Filter through a 0.45 | a, m syringe filter, discard the first ml of filtrate.
    [0434] Chromatographic HPLC conditions:
    [0436] - Column: Xterra RP18, 150 mm long, 4.6 mm internal diameter, 3.5 | a, m particle size or equivalent
    [0437] - Flow rate: 1.0 ml / min
    [0438] - Detection: UV, 215 nm
    [0439] - Injection volume: 10 pl
    [0440] - Data acquisition time: 5 minutes
    [0441] - Pump mode: Isocratic
    [0442] - Column temperature: 30 ° C
    [0444] Precautions During Dissolution Test
    [0446] Saturate the filter with approximately 10 ml of sample solution prior to sample collection. Use prefilter at the end of the dissolution cannula during sample collection in the dissolution container. PVDF 0.45 pin (brand: Millipore or Whatman). During the filtration of samples, avoid trapping of air bubbles in the filter. In case of dissolution profiles, use a separate filter at each time point.
    [0447] Assessment of the suitability of the system
    [0449] Balance the column and the system in the initial composition for 30 minutes. Inject the dissolution medium as a blank into the liquid chromatographic system and record the chromatogram. Inject the STD-I solution five times into the liquid chromatographic system and record the chromatogram. The symmetry factor should not exceed 2.0 for the bilastine peak of the standard chromatogram. The% RSD for the bilastine areas of the peaks of five STD-I injections should not exceed 2.0. Inject STD-II solution in duplicate into the liquid chromatographic system and record the chromatogram. Calculate the similarity factor between two standard preparations. The similarity factor between two standard preparations must be between 0.98 and 1.02.
    [0451] Calculation of the similarity factor
    [0453] _ x. . ,,. x. Average area of STD -I Weight of S TD -II Similarity factor = ------- --------------------------- - x ------------------------ Average area of STD -II Weight of STD -I
    [0455] Process
    [0457] Inject the sample solution into the liquid chromatography and record the chromatogram. The retention time of bilastine is approximately 2.8 minutes.
    [0459] Calculation
    [0461] % At Ws 5 900 of quantity equotated as bilastine = - x ----- x ------ x ------ x P
    [0462] Ace 50 100 Le
    [0464] where
    [0466] At: Area of the peak corresponding to bilastine in the chromatogram of the test solution
    [0467] As: Average area of the peak corresponding to bilastine obtained from the STD-I chromatograms.
    [0468] Ws: Weight of the bilastine working standard used for the preparation of STD-I (mg). Le: Declared on the label of bilastine (mg).
    [0471] P:% potency of the bilastine working standard as found.
    [0473] Table: Comparative Dissolution Profiles of 20 mg Bilastine Tablets with 20 mg Bitosen® in QC Release Media (Acetate Buffer pH 4.5, Paddle - 50 RPM, 900 ml)
    [0475]
    [0478] The dissolution of the inventive formulations of the present invention in QC release media (acetate buffer pH 4.5, paddle - 50 RPM, 900 ml) is comparable to the commercially available reference product (Bitosen ® 20 mg Tabletten). Micronization of API bilastine form 3 does not improve dissolution; it has no significant influence on the dissolution profiles, as is evident from the comparison of the dissolution data of the examples BIL / F3 and BIL / F4 which have the same quantitative composition, but different PSD of API used.
    [0480] Dissolution for comparative examples BIL / CE1 and BIL / CE2 is slower compared to the commercially available reference product (Bitosen ® 20 mg Tabletten) and complete drug release is not achieved even at the 60 min time point ( 82% for BIL / CE1 and 80% for BIL / CE2 versus 97% for Bitosen® Lot 62033).
    [0482] As can be seen from the table above, the dissolution profile for the comparative example BIL / CE4 is not comparable to the reference product (Bitosen ® 20 mg Tabletten) and to the inventive examples, since complete drug release in QC media is not achieved even at the 60 min time point (87% for BIL / CE4 vs 97% for Bitosen® Batch 62033). Profile differences in biorelevant media are even more, as shown in the table below. The examples according to the present invention show dissolution profiles comparable to the commercially available reference product (Bitosen® 20 mg) when evaluated in acetate buffer. Therefore, it can be extracted from these data that the compositions of the present invention, as defined by the additional presence of a water soluble filler, show improved solubility over alternative formulations (such as Patent Document Example 10D WO 2017/017301) which comprises polymorphic form 2 of bilastine. Therefore, the exchange of polymorph 2 for polymorph 3 does not lead to an improvement, as is evident from the dissolution profile of BIL / CE3 (actually, drug release is even slower compared to BIL / CE4). Complete drug release of the BIL / CE3 composition in QC media is not achieved even at the 60 min time point (76% for BIL / CE3 vs 97% for Bitosen® Batch 62033).
    [0484] Table: Dissolution profiles of 20 mg bilastine tablets with 20 mg Bitosen® in biorelevant media (acetate buffer pH 4.5, paddle with dissolution beaker - 30 RPM, 250 ml) together with IVIVC predictions
    [0486]
    [0489] The dissolution of the inventive formulations of the present invention in biorelevant media (acetate buffer at pH 4.5, paddle with 30 RPM dissolution beaker, 250 ml) is comparable to the commercially available reference product (Bitosen ® 20 mg Tabletten), as required to achieve a product bioequivalent to Bitosen®.
    [0491] The comparability with the reference product is also evident when displayed with the in vitro in vivo correlation prediction (IVIVC), calculated with the WinNonlin software based on the dissolution profiles in the biorelevant media. Based on the IVIVC calculation for the BIL / FON2 composition, the predicted Cmax is 97.5%, and the predicted AUC inf is 94%, which is in the required regulatory range of 80-125% for Cmax and AUC. For the BIL / F5 composition, the predicted Cmax is 106.5%, and the predicted AUC inf is 102.3%, which is in the required regulatory range of 80-125% for Cmax and AUC. For the BIL / F6 composition, the predicted Cmax is 102.7%, and the predicted AUC inf is 97.9%, which is in the required regulatory range of 80-125% for Cmax and AUC.
    [0493] As can be seen from the table above, the dissolution profile for the comparative examples BIL / CE1 and BIL / CE2 is not comparable to the commercially available reference product (Bitosen ® 20 mg Tabletten) and the inventive examples, since the release of Drug in biorelevant media is significantly lower at the 60 min time point for the test product compared to the reference product (52% for BIL / CE1 and 56% for BIL / CE2 vs 92% for Bitosen® Batch 62033).
    [0495] The absent comparability of BIL / CE1 and BIL / CE2 with the reference product Bitosen® is also evident from the prediction of IVIVC: the predicted Cmax is 56.2-60.8%, and the predicted AUC is 56.1-60 , 6%, which is significantly below the required regulatory range of 80-125 % for Cmax and AUC.
    [0497] The dissolution profile for the BIL / CE3 comparative example is also not comparable to the reference product (Bitosen ® 20 mg Tabletten) and the inventive examples, as the drug release in the biorelevant media is significantly lower at the 60 time point. min for the test product compared to the reference product (33% for BIL / CE3 vs 92% for Bitosen® Lot 62033). The absent comparability of BIL / CE3 with the reference product Bitosen® is also evident from the prediction of IVIVC: the predicted Cmax is 35.4%, and the predicted AUC is 35.5%, which is significantly below the necessary range. regulatory 80-125 % for Cmax and AUC.
    [0500] Table: Dissolution profiles of BIL / CE4 with Bitosen® 20 mg in 2 ° biorelevant media (acetate buffer at pH 4.5, paddle with dissolution beaker - 25 RPM, 250 ml) together with IVIVC predictions
    [0502]
    [0505] The dissolution profile of the BIL / CE4 composition according to Example 10D of patent document WO 2017/017301 is slower than the reference product Bitosen® and is not acceptable in the 2nd biorelevant media. The same drug release is not achieved even at the 60 min time point (49% vs 86% for Bitosen). The similarity factor (f2 value) is 29. Since the f2 value is below 50, the test product is not identical in solution with the reference product. The absent comparability of BIL / CE4 with the reference product Bitosen® is also evident from the prediction of IVIVC. For the BIL / CE4 composition, the predicted Cmax is 57.6%, and the predicted AUC inf is 56.8%, which is significantly below the required regulatory range of 80-125% for Cmax and AUC.
    [0507] As can be seen from the tables above, the inventive compositions improve with respect to their dissolution times compared to the comparative examples when evaluated using acetate buffer at pH 4.5. The presence of a water-soluble filler therefore allows the improvement of the dissolution of polymorph 3, so that it is comparable to the composition comprising polymorph 1. The dissolution of the inventive formulations of the present invention in acetate buffer at a pH 4.5 is comparable to the commercially available reference product (Bitosen ® 20 mg Tabletten).
    [0508] Part e
    [0510] Uniformity of mixing and uniformity of tablet content:
    [0512] To ensure consistency of dosage units, each unit in a batch must have an active substance content within a narrow range around that declared on the label. Dosage units are defined as dosage forms that contain a single dose or part of a dose of an active substance in each dosage unit. The term "Dosage unit uniformity" is defined as the degree of uniformity in the amount of the active substance between dosage units. Therefore, the requirements of this regulation can be applied to any active substance that is comprised in dosage units containing one or more active substances. The uniformity of pharmaceutical forms (by uniformity of content) was evaluated according to the European Pharmacopoeia 2.9.40. The assay (%) of 10 individual samples (tablets or mixed locations) was detected by HPLC analysis under the following HPLC conditions:
    [0514] Instrumentation
    [0516] - A high-performance liquid chromatography system with isocratic elution capability, a spectrophotometric UV detector, and an autosampler (Waters Alliance 2695 separations module, Waters 2489 dual X absorbance detector or equivalent).
    [0517] - Data manipulation system (Waters Empower workstation or equivalent).
    [0518] - Analytical column: A stainless steel column 150 mm long, 4.6 mm internal diameter filled with octadecylsilylsilica particles as stationary phase with size 3.5 | a, m. (Use: XBridge Shield RP18, 150mm long, 4.6mm ID, 3.5pm particle size or equivalent.)
    [0520] Reagents
    [0522] - Water: HPLC / Milli-Q quality
    [0523] - Acetonitrile: HPLC grade (brand: Merck)
    [0524] - Dipotassium hydrogen phosphate: Emparta quality (brand: Merck)
    [0525] - Orthophosphoric acid: AR quality (brand: Merck)
    [0528] Note: All reagents / solvents can be of the above-mentioned brand or equivalent
    [0530] Mobile phase preparation
    [0532] - Buffer: Prepare anhydrous dipotassium hydrogen phosphate 10 mm. For example, transfer 1.76 gm of anhydrous dipotassium hydrogen phosphate to a beaker containing 1000 ml of Milli-Q grade water. Adjust the pH to 6.8 with dilute orthophosphoric acid. Filter through a 0.45 | a, micron or finer porosity membrane filter and degas.
    [0533] - Mobile phase: Buffer: Acetonitrile (70:30 v / v).
    [0534] - Preparation of diluent: Mix water and acetonitrile in the ratio of 50:50 (v / v) and degas.
    [0536] Chromatographic conditions
    [0538] - Column: XBridge Shield RP18, 150 mm long, 4.6 mm internal diameter, 3.5 | a, m particle size or equivalent.
    [0539] - Flow rate: 1.0 ml / min
    [0540] - UV detection, 215 nm
    [0541] - Injection volume: 10 | a, l
    [0542] - Data acquisition time: 8 minutes
    [0543] - Column temperature: 30 ° C
    [0544] - Pump mode: Isocratic
    [0546] Preparation of solutions
    [0548] Standard solution: Prepare a solution containing 0.08 mg / ml of bilastine in diluent. For example, accurately weigh 50 mg of bilastine working standard into a clean, dry 50 ml volumetric flask. Add 15 ml of diluent and sonicate until dissolved. Make up the volume with diluent and mix. Dilute 4.0 ml of this solution to 50 ml with diluent. Label this working standard solution STD-I. Prepare the working standard solution in duplicate and label it STD-II.
    [0550] Sample solution: For example: Carefully transfer the entire amount of sample from the glass vial to a 200 ml volumetric flask using a funnel. Rinse the vial
    [0553] completely with water and transfer the rinse volume to the same volumetric flask. Repeat the vial procedure rinse at least 3 times so that the entire sample is transferred to the volumetric flask. Add 50 ml of diluent, shake for 20 minutes at 150 RPM. Add 50 ml of diluent and sonicate for 15 minutes with intermittent shaking, make up the volume with diluent. Shake well and filter through 0.45 micron filtration membrane. Further dilute 5 ml to 20 ml with thinner.
    [0555] Assessment of the suitability of the system
    [0557] - Balance the column and the system to the initial composition for 30 minutes.
    [0558] - Inject the diluent as a blank into the liquid chromatographic system and record the chromatogram.
    [0559] - Inject the STD-I solution five times into the liquid chromatographic system and record the chromatogram.
    [0560] - The symmetry factor must not exceed 2.0 for the bilastine peak of the standard chromatogram. The retention time of the bilastine peak is approximately 4.7 minutes.
    [0561] -% RSD for the bilastine peak areas of five STD-I injections should not be greater than 2.0.
    [0562] - Inject the STD-II solution in duplicate into the liquid chromatographic system and record the chromatogram.
    [0563] - Calculate the similarity factor between two standard preparations. The similarity factor between two standard preparations must be between 0.98 and 1.02.
    [0565] Calculation of the similarity factor
    [0567] _ x. . ,,. x. Average area of STD -I Weight of S TD -II Similarity factor = - Á ------ -------------------------- - x ------------------------ Average area of STD -II Weight of STD -I
    [0569] Calculation
    [0571] At Ws 4 200 20 LQ
    [0572] Assay (% declared on label) = - x ----- x - x ------ X ----- X ------- X P
    [0573] As 50 50 Wt 5 LC
    [0575] where
    [0576] At: Area of the peak corresponding to bilastine in the chromatogram of the test solution
    [0577] As: Average area of the peak corresponding to bilastine obtained from the STD-I chromatograms.
    [0578] Ws: Weight of the bilastine working standard used for the preparation of STD-I (mg). Wt: Sample weight (mg)
    [0579] Le: Declared on the label of bilastine (mg).
    [0580] P:% assay of the bilastine working standard as found.
    [0581] LQ: Label Amount of Bilastine (mg).
    [0583] The results are presented in the table below.
    [0585] Table: Results of the evaluation of the uniformity and test of the content of tablets Lot BIL / F6
    [0590] As can be seen from the data presented above, the content uniformity is within the specification limits according to the European Pharmacopoeia 2.9.40. Furthermore, both the tablet test and the average amount of API contained per tablet (as described above under "Average") demonstrate a value of 101.5% and 102.3%, correspondingly, which clearly meets the 95-105% standard requirements.
    [0593] Part f
    [0595] Stability studies:
    [0597] 20 mg bilastine tablets were loaded under the conditions mentioned below and the tablets were analyzed for dissolution at the respective time point.
    [0599] Table: Dissolution profiles of the BIL / CX formulation with form 2 (Initial and 1 month at 40 ° C / 75% RH in Alu-Alu blister) compared to Innovator in QC release medium (acetate buffer at pH 4.5, paddle, 50 RPM, 900 mi)
    [0604] As can be seen from the table above, the dissolution profile of the BIL / CX formulation with form 2 shows a slight drop in the dissolution profile at the 5-20 minute time point of the experiment, seen after 1 month of storage. in Alu-Alu blister under accelerated ICH conditions (40 ° C / 75% RH).
    [0606] The inventive 20 mg bilastine tablets were loaded under the conditions mentioned below and the tablets were analyzed in the corresponding tests (Dissolution, Related Substance and Assay) at the respective time point.
    [0609] Table: Stability data of BIL / F6 in accelerated condition of ICH (40 ° C / 75% RH, Alu - Alu blister pack)
    [0614] As can be seen from the table above, the dissolution profile of the test formulation BIL / F6 with the addition of mannitol shows comparable dissolution profile after 1 month of storage of the tablets under accelerated conditions of ICH (40 ° C / 75 % RH in Alu-Alu blister), when compared to fresh tablets. No changes are observed (such as a drop in the dissolution profile in the 5-20 minute time frame of the experiment). There is also no significant influence of the temperature and humidity observed in Bilastine Related Substances. Furthermore, the tablet test demonstrates a value of 101.5% (initial) and 97.5% (after 1 month), correspondingly, which clearly meets the standard requirements of 95-105 %.
    [0615] Table: Stability data of BIL / F6 in ICH long-term condition (25 ° C / 60% RH, Alu - Alu blister pack)
    [0620] As is evident from the table above, there is no significant influence on the temperature and humidity observed in Solution and Related Substances of Bilastine in the selected composition of BIL / F6 after storage under long-term ICH conditions for 1 month in Alu blister. -Alu. In addition, the tablet test shows a value of 101.5% (initial) and 97.5% (after 1 month long-term storage), correspondingly, which clearly meets the standard requirements of 95-105%.
    [0623] Table: Related Substance Data under ASAP conditions for BIL / F6 in open exposure
    [0625]
    [0628] As is evident from the table above, the data for related substances in all ASAP conditions in open exposure were found to be satisfactory as impurity levels are low (no more than 2% m / m).
    [0630] Part G
    [0632] Polymorphic API analysis:
    [0634] XRD analysis of the API before and after micronization confirms that the API remains in polymorphic 3 form unchanged during the micronization process.
    [0636] The corresponding powder X-ray diffraction results are demonstrated in the figures below (Figures 3 and 4).
    [0638] During the first micronization tests of the pure polymorphic form 2, the presence of form 3 and the dihydrate form A were observed as polymorphic impurities in some
    [0641] cases after jet grinding. For example, two out of five batches of the micronized API have shown contamination of form 2 with form 3 and dihydrate form A.
    [0643] Polymorphic stability of tablets:
    [0645] Further analysis has also demonstrated high stability of polymorphic form 3 in the compositions of the present invention. Evaluation of the polymorphic stability of the API was carried out on the tablets produced as described above using X-ray powder diffraction (XRD) analysis of fresh and stored tablets.
    [0647] The physical (polymorphic) and chemical stability of the inventive tablet pharmaceutical composition can be tested in a conventional way, in particular under long-term conditions (25 ° C / 60% RH in commercial blister pack) and under accelerated conditions ( at 40 ° C / 75% RH in commercial blister pack) according to ICH Q1 A (R2) guidelines. Typically a 2-week Accelerated Stability Assessment Program ( ASAP) is applied according to Waterman 2011 ( Waterman KC, The application of the Accelerated Stability Assessment Program ( ASAP) to quality by design ( QbD) for drug product stability, AAPS PharmSciTech, Vol. 12, No.3, September 2011) for a faster estimate of chemical stability and for a more accurate prediction of shelf stability compared to ICH stability. Analogously to chemical stability, an ASAP study can be applied for rapid estimation of the physical stability of a composition or an accurate relative comparison of the polymorphic stability of two different compositions.
    [0649] Compositions according to BIL / F3 and BIL / F6 were evaluated by powder XRD at the initial time point and after storage (open exposure or Alu-Alu blister) under various conditions of temperature and humidity, for example:
    [0651] 1) after the ICH stability study under long-term conditions (25 ° C / 60% RH in Alu-Alu blister),
    [0652] 2) after the ICH stability study under accelerated conditions (40 ° C / 75% RH in Alu-Alu blister),
    [0653] 3) after ASAP study under stress conditions (eg, open exposure at 50 ° C / 75% RH 14 days).
    [0654] The results are presented in the table below.
    [0656] Table: Overview of polymorphic stability studies
    [0658]
    [0661] As shown in the table above, the powder X-ray diffraction analysis of the API in the produced tablets, as described above according to BIL / F3, shows that only the 3 polymorphic form is present at the initial time point and also after 1 month storage under accelerated ICH conditions (40 ° C / 75% RH, 1 month in Alu-Alu blister).
    [0663] The accelerated stability test as explained above has been carried out according to the applicable pharmaceutical regulatory standards as described in the ICH Q1A (R2) standard, where the pharmaceutical composition in tablets has been packed in Alu-Alu blisters.
    [0665] The bilastine API used in the BIL / CX tablet composition is polymorphic form 2. The amount of polymorphic impurity (dihydrate form A) measured for the composition initially after production is below the limit of detection, and was only detected bilastine form 2. When regulatory accelerated stability assessment standards are used as storage conditions, the composition of
    [0668] The tablet is sealed in Alu-Alu blisters and the amount of polymorphic impurity (dihydrate form A) is still below the detection limit after 1 month of storage. Consequently, the pharmaceutical tablet compositions according to the BIL / CX example do not show physical instability (polymorphic transformation) within one month of accelerated storage.
    [0670] For the BIL / CX composition, trace contamination of the dihydrate form A is observed in the ASAP study after open exposure storage at high temperature / high humidity (50 ° C / 75% RH) for 14 days. This polymorphic impurity was found only at these high temperature / high humidity conditions and only after the maximum storage time in the ASAP study (2 weeks).
    [0672] At lower humidity, this polymorphic impurity has not been detected even at higher temperatures (eg 70 ° C / 5% RH, 14 days). At a shorter storage time, this polymorphic impurity has also not been detected even at higher temperatures (eg 70 ° C / 75% RH, 2 days).
    [0674] X-ray powder diffraction analysis of API powder in tablets produced as described above according to inventive Example BIL / F6 shows that only polymorphic form 3 is present at the initial time point and after 14 days of storage under stress at high temperature / high humidity (50 ° C / 75% RH, open exposure). The ASAP data as explained above already suggests that commercial Alu-Alu blister-packed BIL / F6 tablets will not show impurity of dihydrate form A after long-term and accelerated storage of ICH, as the rate of Water vapor transmission (WVTR) for the Alu-Alu blister is minimized. The finding is confirmed by XRD results after 2 months of storage in Alu-Alu blister under accelerated ICH conditions (40 ° C / 75% RH) and long-term conditions (25 ° C / 60% RH ).
    [0676] For an accurate comparison of physical (polymorphic) stability of two compositions BIL / CX (with form 2) and BIL / F6 (with form 3), the XRD results after the most stressful conditions in the ASAP study are more suitable . Unlike as in the BIL / CX composition, no traces of polymorphic impurity of the dihydrate form A in tablets according to BIL / F6 are detected after 14 days of open exposure storage at high temperature / high humidity (50 ° C / 75% RH) showing that the BIL / F6 composition is more stable polymorphic than BIL / CX. Therefore, you can expect greater shelf stability for the pharmaceutical tablets according to the BIL / F8 example in the same packaging material (Alu-Alu) or a much cheaper blister with higher water vapor transmission speed, such as PVC blister, could be used, as commercial primary packaging.
    [0678] The above stability results for the tablets are unexpected in view of the state of the art, since the patent document WO 2017/017301 is disclosing that the bilastine API form 2 is stable on storage, while the API form 3 Bilastine is partially converted to form 1 leading to a mixture of form 3 with form 1 after 1 month storage at 25 ° C / 60% RH (long-term ICH conditions) and at 40 ° C / 75% of HR (accelerated ICH conditions), and the phase transformation increases further after 2 months under accelerated conditions to provide a mixture of Form 1 with Form 3.
    [0680] The exemplary X-ray powder diffraction results are shown below in the figures (Figures 1-12).
    [0682] X-ray powder diffraction analysis of API Bilastine Form 1 (Fig. 1) and Form 2 (Fig. 2) is done according to "XRD Method D1" below.
    [0684] Non-micronized bilastine API form 3 (Fig. 3) is analyzed according to the "XRD method V1".
    [0686] PXRD analysis of micronized API bilastine form 3 (Fig. 4) and 3 BIL / F6 tablet samples (Figures 10-12) is done by "XRD method A1".
    [0688] Bilastine dihydrate form A (Fig. 5) and BIL / CX and BIL / F3 tablet samples (Figures 6-9) are analyzed using the "XRD method V2".
    [0690] XRD Method D1:
    [0692] Qualitative measurements of PXRD were performed using the X'Pert MPD system, LLF X-ray source with CuKa radiation, 0.02, 0.04 rad Soller collimators, 1/2 degree divergent slot, the dust load was 400 mg. The radiation used - CuKa (8 keV); 40 kV-40 mA; measurement range 0-40 degrees, measurement time per sweep - 2.5 hours, stage = 0.013 ° 20. During measurements the sample was rotated at the speed 4 s / revolution to improve counting statistics.
    [0694] XRD Method V1:
    [0696] A summary of the XRD method parameters is described below.
    [0698] Model / Brand: Bruker AXS / D8 Advance
    [0699] X-ray tube: Copper Ka1, 1.5406 A
    [0700] Detector: Lynx Eye
    [0701] Filter K (3: Nickel
    [0702] Sweep interval (° 20): 3- 40
    [0703] Stage Size (20 °): 0.016 °
    [0704] Current: 40 mA
    [0705] Voltage: 40 kV
    [0706] Sweep type: Closed coupled and continuous
    [0707] Centrifugation: 30 rpm
    [0708] Divergence slot: 0.3 °
    [0709] Anti-scatter groove: 3mm
    [0710] Sweep time: 20 min
    [0712] Preparation of sample:
    [0714] Fill the fine powder into the round cavity of the sample holder and smooth the surface with glass plate / slide to obtain a smooth surface. The surface of the specimen must be parallel to the surface of the support and free of cracks and fissures. Clean the outer edges of the support with tissue paper to avoid contamination of the samples.
    [0716] Place the carefully prepared sample holder on the XRD instrument sample plate and analyze under the conditions of the above method at room temperature using the Difrac plus software.
    [0718] XRD Method A1:
    [0720] A summary of the XRD method parameters is described below.
    [0722] Model / Brand: PANalytical / EMPYREAN
    [0725] X-ray tube: Ka1 copper
    [0726] Wavelength (A) 1.5406
    [0727] Detector: PIXcel 1D
    [0728] Reflection analysis mode
    [0729] Sweep range (° 20): 3 - 40
    [0730] Stage Size (20 °): 0.013
    [0731] Current: 40 mA
    [0732] Voltage: 45 kV
    [0733] Sweep Type: Closed Coupled, Continuous
    [0734] Centrifugation: 30 rpm
    [0735] Divergence slot: 0.25 °, fixed
    [0736] Anti-scatter groove: 0.5 °, fixed
    [0737] Sweep time: 1 hour
    [0739] Preparation of sample
    [0741] API Sample : The API powder sample is measured as is.
    [0743] Tablet samples'. Take four tablets, grind to fine powder using gently mortar and agate pistil.
    [0745] Prepare the sample (approximately 350 mg) using the PANanalytical sample preparation kit by 'post-loading technique' *. The sample surface must be smooth and parallel to the surface of the holder. Clean the outer edges of the sample holder with tissue paper to avoid sample contamination.
    [0747] * Preparation of samples by the ‘post-loading technique’
    [0749] - Make sure the sample holder ring is securely attached to the preparation table.
    [0750] - Put the sample in the holder ring and compress the sample powder down firmly using the press block.
    [0751] - Remove all excess dust above the edge of the support ring using a scraper and brush.
    [0752] - Put the bottom plate on the support ring and fix it in position.
    [0753] - Remove the complete sample holder from the preparation table by turning the table upside down preparation and pressing the spring loaded button.
    [0755] XRD Method V2:
    [0757] A summary of the XRD method parameters is described below.
    [0759] Model / Brand: Bruker AXS / D8 Advance
    [0760] X-ray tube: Copper Ka1, 1.5406 A
    [0761] Detector: Lynx Eye
    [0762] Filter K (3: Nickel
    [0763] 20 start: 3.0 °
    [0764] 20 end: 40.0 °
    [0765] Stage Size (20 °): 0.016 °
    [0766] Current: 40 mA
    [0767] Voltage: 40 kV
    [0768] Sweep type: Closed coupled and continuous
    [0769] Centrifugation: 30 rpm
    [0770] Divergence slot: 0.3 °
    [0771] Receiver slot: 3mm
    [0772] Total time: 1 hour
    [0774] Preparation of sample:
    [0776] API Sample: The API powder sample is measured as is.
    [0778] Tablet samples'. Take four tablets, crush into a fine powder using a neat and clean mortar and pestle.
    [0780] Fill the fine powder into the round cavity of the sample holder and smooth the surface with glass plate / slide to obtain a smooth surface. The surface of the sample must be parallel to the surface of the holder. Clean the outer edges of the support with tissue paper to avoid contamination of the samples.
    [0782] Place the prepared sample holder on the XRD instrument sample plate and analyze according to the above method at room temperature.
    [0783] Part h
    [0785] Comparison with Examples 2 and 4 of patent document CN106692090A:
    [0787] These data were prepared to highlight the observations associated with tests carried out according to 2 and 4 of patent document CN106692090A (Comparative Examples).
    [0789] Table: Test with compositions according to Examples 2 and 4 of patent document CN106692090A (Comparative Examples)
    [0791]
    [0792] General procedure:
    [0794] 1) Sift the API through No. 100 mesh
    [0795] 2) Sift intragranular ingredients from Stage A through No. 80 mesh.
    [0796] 3) Load the sieved ingredients in Step A into a fast mixer-granulator and mix for 10 min at slow speed with impeller ON and blade OFF.
    [0797] 4) Granulate the material from Step 3 using binder solution from Step B. 5) Sift the wet material from Step 4 using No. 18 mesh sieve to get wet granules.
    [0798] 6) Dry the granules of material from Step 5 in a Retch speed dryer at 50 ° C, air flow 10 for 1.5 hours.
    [0799] 7) Roll the dried granules from Step 6 through # 20 mesh.
    [0800] 8) Sift the extragranular ingredients from Step C, except magnesium stearate, through No. 80 mesh.
    [0801] 9) Sift the magnesium stearate from Step C through 35 mesh (or appropriate size).
    [0802] 10) Load the materials from Stage 7 and Stage 8 into a suitable mixer and lubricate them using sieved magnesium stearate from Stage 9 for 5 min at 20 rpm.
    [0803] 11) Compress the tablets on a rotary tablet compression machine using a 6.00mm round biconcave bur.
    [0805] Table: Physical parameters of tablets
    [0810] The breakdown time of the test batches is in line with the reference product. No tackiness trend was observed during compression for BIL / CE5. Tack was observed during compression for BIL / CE6.
    [0813] Table: P-XRD analysis of tablets.
    [0815]
    [0818] As shown in the table above, qualitative analysis shows that the compositions manufactured according to Examples 2 and 4 of patent document CN106692090A using wet granulation lead to polymorphic instability, thus showing that these manufacturing methods and compositions are not capable of provide a solution to the problem of providing a stable bilastine composition based on polymorphic form 3.
    [0820] Table: Comparative dissolution profiles of 20 mg bilastine tablets with 20 mg Bitosen® in acetate buffer at pH 4.5, dissolution beaker paddle - 30 RPM, 250 ml
    [0822]
    [0826] Table: Comparative dissolution profiles of 20 mg bilastine tablets with 20 mg Bitosen® in acetate buffer at pH 4.5, paddle - 50 RPM, 900 ml
    [0831] The tests carried out with comparative examples according to 2-4 of the patent document CN106692090A show polymorphic transformation of the pure form 3 (in Lot No. BIL / CE5 and Lot No. BIL / CE6) in the 'Bilastine dihydrate form A', suggesting that wet granulation is not the appropriate method for the development of bilastine tablets using Form 3 API.
    [0833] The dissolution profiles of the comparative examples according to 2-4 of the patent document CN106692090A show faster dissolution profiles than the reference product Bitosen® in the QC release medium. However, the dissolution profiles were considerably slow and incomplete in the biorelevant dissolution medium for all runs. The IVIVC predictions of Cmax and ABC suggest that the BIL / CE5, BIL / CE6 lots are not identical or functionally similar to the reference product.
    权利要求:
    Claims (26)
    [1]
    1. A pharmaceutical composition in the form of a tablet, comprising a) a crystalline form 3 of bilastine, wherein the crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70 and 17.71 ± 0, 2 degrees 2-theta in a powder X-ray diffraction pattern, b) a water soluble filler, and optionally c) a water insoluble filler.
    [2]
    2. The pharmaceutical composition according to claims 1 or 2, wherein the composition further comprises a disintegrant, a slipper and / or a lubricant.
    [3]
    3. The pharmaceutical composition according to any one of the preceding claims, wherein the water-soluble filler is a sugar.
    [4]
    4. The pharmaceutical composition according to any one of the preceding claims, wherein the water soluble filler is mannitol.
    [5]
    5. The pharmaceutical composition according to any one of the preceding claims, wherein the water-soluble filler is lactose.
    [6]
    6. The pharmaceutical composition according to any one of the preceding claims, wherein the water-insoluble filler is microcrystalline cellulose.
    [7]
    7. The pharmaceutical composition according to any one of the preceding claims, wherein the disintegrant is selected from sodium starch glycolate, low-substituted hydroxypropylcellulose, pregelatinized starch or crospovidone, preferably sodium starch glycolate or crospovidone.
    [8]
    8. The pharmaceutical composition according to any one of the preceding claims, wherein the glidant is silicon dioxide, preferably as colloidal anhydrous silica, magnesium aluminometasilicate and / or talc.
    [9]
    9. The pharmaceutical composition according to any one of the preceding claims, wherein the glidant is a combination of silicon dioxide and magnesium aluminometasilicate.
    [10]
    10. The pharmaceutical composition according to any one of the preceding claims, in
    4
    where the lubricant is magnesium stearate.
    [11]
    11. The pharmaceutical composition according to any one of the preceding claims, comprising a crystalline form 3 of bilastine, wherein crystalline form 3 has characteristic peaks at 6.47, 12.81, 15.70, and 17.71 ± 0 , 2 degrees 2-theta in a powder X-ray diffraction pattern, a water-soluble filler, a water-insoluble filler, a disintegrant, a glider, and a lubricant, where the water-soluble filler is mannitol and the glider it is colloidal anhydrous silica or a combination of silicon dioxide and magnesium aluminometasilicate.
    [12]
    12. The pharmaceutical composition according to any one of the preceding claims, wherein the water-soluble filler is D-mannitol, the water-insoluble filler is microcrystalline cellulose, the disintegrant is sodium starch glycolate, the glidant is colloidal anhydrous silica or a combination of colloidal anhydrous silica and magnesium aluminometasilicate and the lubricant is magnesium stearate.
    [13]
    The pharmaceutical composition according to any one of the preceding claims, comprising:
    - Polymorphic form 3 of bilastine in an amount (% by weight of the tablet) of 10-20%, preferably 12-18%, more preferably 16%;
    - Mannitol in an amount of 40-70%, preferably 50-65%, more preferably 61%;
    - Microcrystalline cellulose in an amount of 10-30%, preferably 12-20%, more preferably 14%;
    - Sodium starch glycolate in an amount of 0.1-5%, preferably 2.5-4.5%, more preferably 4%;
    - Colloidal anhydrous silica in an amount of 0.1-5%, preferably 2-4%, more preferably 2.8%; and
    - Magnesium stearate in an amount of 0.1-5%, preferably 1-3 %.
    [14]
    14. The pharmaceutical composition according to any one of claims 1-12, comprising:
    - Polymorphic form 3 of bilastine in an amount (% by weight of the tablet) of 10-20%,
    - Mannitol in an amount of 40-70%,
    - Microcrystalline cellulose in an amount of 10-30%,
    - Sodium starch glycolate in an amount of 0.1-5%,
    - Colloidal anhydrous silica in an amount of 0.1-5%,
    - Magnesium aluminometasilicate in an amount of 0.1-5%, and
    - Magnesium stearate in an amount of 0.1-5%.
    [15]
    15. The pharmaceutical composition according to any one of claims 1-12, comprising:
    - Polymorphic form 3 of bilastine in an amount (% by weight of the tablet) of 12 18%, more preferably 16%;
    - Mannitol in an amount of 50-65%, more preferably 61%;
    - Microcrystalline cellulose in an amount of 12-20%, more preferably 14%; - Sodium starch glycolate in an amount of 2.5-4.5%, more preferably 4%; - Colloidal anhydrous silica in an amount of 0.5-2%, more preferably 0.8%;
    - Magnesium aluminometasilicate in an amount of 1-3%, more preferably 2%; and
    - Magnesium stearate in an amount of 1-3%, more preferably 1.6%.
    [16]
    16. The pharmaceutical composition according to any one of claims 1-12, comprising:
    - Polymorphic form 3 of bilastine in an amount (% by weight of the tablet) of 12 18%, more preferably 16%;
    - Mannitol in an amount of 50-65%, more preferably 58%;
    - Microcrystalline cellulose in an amount of 15-25%, more preferably 20%; - Sodium starch glycolate in an amount of 0.5-2%, more preferably 1.2%; - Colloidal anhydrous silica in an amount of 0.5-2%, more preferably 0.8%;
    - Magnesium aluminometasilicate in an amount of 1-3%, more preferably 2%; and
    - Magnesium stearate in an amount of 1-3%, more preferably 1.6%.
    [17]
    17. The pharmaceutical composition according to any one of the preceding claims, wherein the tablet is a coated or uncoated immediate release tablet, preferably uncoated.
    [18]
    18. The pharmaceutical composition according to any one of the preceding claims, wherein said composition is prepared by an essentially dry process without wet granulation.
    [19]
    19. The pharmaceutical composition according to any one of the preceding claims, wherein said composition is prepared by dry granulation of a mixture of the components of at least claim 1 and optionally one or more of the additional components of any one or more of the preceding claims, and compressing the granules into a tablet.
    [20]
    20. The pharmaceutical composition according to any one of the preceding claims, wherein said composition is prepared by granulating a mixture of the components of claim 1 together with the additional components of any one or more of the preceding claims, roller compaction and granulation of the mixture, grinding of the granules, lubrication of the granules and subsequent compression of the granules into a tablet.
    [21]
    21. The pharmaceutical composition according to any one of claims 1 to 14, wherein said composition is prepared by direct compression of a mixture of the components of claim 1 and optionally one or more of the additional components of any one or more of the previous claims.
    [22]
    22. The pharmaceutical composition according to any one of the preceding claims for use as a medicament in the treatment of allergic rhinoconjunctivitis and / or urticaria.
    [23]
    23. Method of preparing a pharmaceutical composition in the form of a tablet according to any one of the preceding claims, wherein said composition is prepared by an essentially dry process without wet granulation.
    [24]
    24. Method of preparing a pharmaceutical composition in the form of a tablet, wherein said composition is prepared by dry granulation of a mixture of the components of at least claim 1 and optionally one or more of the additional components of any one or more of the preceding claims, and compressing the granules into a tablet.
    7
    [25]
    25. Method of preparing a pharmaceutical composition in the form of a tablet, wherein said composition is prepared by granulating a mixture of the components of claim 1 together with the additional components of any one or more of the preceding claims, compaction by roller and granulation of the mixture, grinding of the granules, lubrication of the granules and subsequent compression of the granules into a tablet.
    [26]
    26. Method of preparing a pharmaceutical composition in the form of a tablet, wherein said composition is prepared by direct compression of a mixture of the components of claim 1 and optionally one or more of the additional components of any one or more of the previous claims.
    类似技术:
    公开号 | 公开日 | 专利标题
    ES2645008T3|2017-12-01|Solid dosage forms of bendamustine
    ES2811110T3|2021-03-10|Pharmaceutical composition capable of incorporating Lenalidomide in various crystalline modifications
    KR101840182B1|2018-03-19|Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-|-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
    KR101977785B1|2019-05-14|Composite formulation for oral administration comprising ezetimibe and rosuvastatin and a process for the preparation thereof
    JP5798641B2|2015-10-21|Pharmaceutical composition for oral administration
    KR20150079454A|2015-07-08|Composite formulation for oral administration comprising ezetimibe and rosuvastatin
    JP2020512350A|2020-04-23|Nilaparib composition
    ES2695099T3|2019-01-02|Pharmaceutical formulations
    KR20120098878A|2012-09-05|Elution-stabilized preparation
    ES2813561T3|2021-03-24|Pharmaceutical composition in tablet comprising bilastine
    EP2497464A2|2012-09-12|Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture
    ES2835287T3|2021-06-22|Pharmaceutical tablet composition comprising polymorphic form 3 of bilastine and magnesium aluminometasilicate
    ES2864176T3|2021-10-13|Pharmaceutical tablet composition comprising bilastine form 3 and a water soluble filler
    JP6839708B2|2021-03-10|8-[| -3-amino-1-piperidinyl] -7- | -3,7-dihydro-3-methyl-1- [4-methyl-2-quinazolinyl) methyl ] -A pharmaceutical composition containing -1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof.
    BR112019015487A2|2020-03-31|CRYSTALLINE FORMS OF PIVOXIL TEBIPENEM, COMPOSITIONS INCLUDING THE SAME, MANUFACTURING METHODS AND METHODS OF USE
    JP2018525422A|2018-09-06|Pharmaceutical composition comprising 3- | -piperidine-2,6-dione
    ES2693156T3|2018-12-07|Sustained-release tablet containing levodropropizine and method to prepare it
    KR102330953B1|2021-11-26|Pharmaceutical dosage forms containing sodium-1-[6-|pyrimidin-4-yl]-4-|-1h-pyrazol-5-olate
    KR102308227B1|2021-10-05|Oral tablet composition containing sunitinib
    JP4393119B2|2010-01-06|Preparation containing iodopropamide
    US20160022661A1|2016-01-28|Dosage Form Comprising Crizotinib
    BR112020006599A2|2020-10-06|cis-4- [2 - {[| -3-fluoro-oxan-4-yl] amino} -8- | -9h-purin compositions and methods of use 9-yl] -1-methylcyclohexane-1-carboxamide
    EP2803352A1|2014-11-19|High dose imatinib tablets
    JP2020510027A5|2021-04-22|
    RU2517216C2|2014-05-27|Pharmaceutical composition of imatinib or its pharmaceutically acceptable salt, method for preparing it and method| of treating
    同族专利:
    公开号 | 公开日
    EP3641735A1|2020-04-29|
    WO2019097091A1|2019-05-23|
    EP3641735B1|2021-02-24|
    ES2773756R1|2021-04-12|
    ES2864176T3|2021-10-13|
    PL3641735T3|2021-09-06|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    ES2124167B1|1996-06-04|1999-09-16|Espanola Prod Quimicos|NEW DERIVATIVES OF BENZMIDAZOLE WITH ANTIHISTAMINE ACTIVITY.|
    WO2003089425A1|2002-04-19|2003-10-30|Faes Farma, S.A.|Polymorph of acid 4-[2-[4-[1--1h-benzimidazole-2-il]-1-piperidinyl]ethyl]-$g, $g-dimethyl-benzeneacetic|
    CZ307500B6|2012-08-15|2018-10-24|Zentiva, K.S.|A method of the preparation of a 2-methyl-2'-phenylpropionic acid derivative employing novel intermediates|
    SK7066Y1|2014-01-29|2015-03-03|Zentiva Ks|Crystalline dihydrate bilastine|
    CN104398481A|2014-10-29|2015-03-11|万全万特制药江苏有限公司|Bilastine orally disintegrating tablet and preparing method thereof|
    EP3327012B1|2015-07-24|2021-03-17|Urquima, S.A.|Crystalline forms of bilastine and preparation methods thereof|
    WO2017167949A1|2016-04-01|2017-10-05|Krka, D.D., Novo Mesto|Crystalline forms of bilastine|
    CN106692090A|2017-02-14|2017-05-24|万全万特制药（厦门）有限公司|Bilastine tablets and preparation method thereof|
    法律状态:
    2020-07-14| BA2A| Patent application published|Ref document number: 2773756 Country of ref document: ES Kind code of ref document: A2 Effective date: 20200714 |
    2021-04-12| EC2A| Search report published|Ref document number: 2773756 Country of ref document: ES Kind code of ref document: R1 Effective date: 20210405 |
    2021-08-02| FA2A| Application withdrawn|Effective date: 20210727 |
    优先权:
    申请号 | 申请日 | 专利标题
    IN201711045443|2017-12-18|
    EP18154203.6A|EP3470062B1|2017-12-18|2018-01-30|Pharmaceutical tablet composition comprising bilastine polymorphic form 3 and magnesium aluminometasilicate|
    IN201811041577|2018-11-02|
    PCT/EP2018/085448|WO2019097091A1|2017-12-18|2018-12-18|Pharmaceutical tablet composition comprising bilastine form 3 and a water-soluble filler|
    [返回顶部]